nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-CA249C02·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Electrical and Electronic Engineering·Basis: Full text·Type: Diagnostic accuracy study

Ultrasensitive Detection of Neurofilament Light in Plasma Using F(Ab')2-Modified Graphene Field-Effect Biosensor.

Kizilates et al.Kizilates, Asrosa, Senicar et al.·2026·Small (Weinheim an der Bergstrasse, Germany)·10.1002/smll.73928 ↗

Primary claim

Compared with whole antibody-based GFETs, this F(ab')2-modified GFET platform is shown to achieve a 114% increase in sensitivity, a fivefold improvement in the limit-of-detection down to 0.18 pg/mL.

Supported · direct IgG comparison supports the direction, but diluted-matrix calibration and incomplete independent-unit accounting limit certainty
In brief

F(ab')2 functionalization improves GFET detection of NfL in diluted plasma, but five clinical samples cannot establish diagnostic validation.

ReliabilityNo concerns4 of 4 checks completeSee what was checked ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Neurofilament light (NfL) is a discriminative blood biomarker for many neurological diseases. Current accurate analysis relating to NfL relies on state-of-the-art technologies such as the single-molecule array (Simoa) and immunoprecipitation-mass spectrometry (IP-MS), which require complicated machinery, skilled operational personnel, and well-equipped laboratories. Herein, we demonstrate a robust on-chip graphene field-effect transistor (GFET) biosensing platform for the ultrasensitive detection of NfL. This work utilizes smaller antibody fragments F(ab')2 to mitigate Debye screening and enhance sensing performance, alongside quantitative characterization of 1-pyrenebutyric acid N-hydroxysuccinimide ester (PBASE) surface density to support controlled antibody immobilization. Compared with whole antibody-based GFETs, this F(ab')2-modified GFET platform is shown to achieve a 114% increase in sensitivity, a fivefold improvement in the limit-of-detection (LoD) down to 0.18 pg/mL, and a wide dynamic detection range from 0.18 to 1500 pg/mL, together with good selectivity, stability, and reproducibility. This biosensing platform is validated against Simoa technology for the detection of NfL in clinical plasma samples, yielding a high correlation coefficient of 0.99. These results demonstrate the potential of GFETs for point-of-care diagnosis and the monitoring of neurological diseases in frontline clinical settings, outperforming conventional immunoassays and approaching Simoa sensitivity.

Key Claims

Primary finding · Supported

Compared with whole antibody-based GFETs, this F(ab')2-modified GFET platform is shown to achieve a 114% increase in sensitivity, a fivefold improvement in the limit-of-detection down to 0.18 pg/mL.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

direct IgG comparison supports the direction, but diluted-matrix calibration and incomplete independent-unit accounting limit certainty

Abstract; Results, Performance of GFET Devices, Figure 4B
Quote verified
Secondary · Tentative

This biosensing platform is validated against Simoa technology for the detection of NfL in clinical plasma samples, yielding a high correlation coefficient of 0.99.

five samples, correlation without agreement analysis, and 123% recovery cannot establish clinical validation

Abstract; Results, Clinical Sample Measurements with GFET and Simoa, Figure 5B–C
Quote verified
Secondary · Tentative

This work utilizes smaller antibody fragments F(ab')2 to mitigate Debye screening and enhance sensing performance.

the fragment advantage appears only in highly diluted media and disappears at higher ionic strength

Abstract; Results, Performance of GFET Devices, Figure 4C
Quote verified
Secondary · Supported

At 0.001x and 0.01x PBS, F(ab')2 aNfL-immobilized GFETs exhibited significantly greater responses compared to their IgG counterparts.

a direct fixed-concentration ionic-strength comparison supports the stated result under the tested conditions

Results, Performance of GFET Devices, Figure 4C
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Direct fragment-versus-IgG analytical comparison

F(ab')2 and whole-IgG GFETs are compared across the same concentration range, with reported improvements in slope, LoD, and variability. The ionic-strength series further tests when the fragment advantage appears.

↳ Results, Performance of GFET Devices, Figure 4B–C

#contribution

Orthogonal surface chemistry characterization

PBASE adsorption and density are assessed through Raman spectroscopy, XPS, AFM, QCM-D, and transfer-curve analysis. QCM-D, electrical, and XPS estimates converge within a relatively narrow range.

↳ Results, Molecular Density of PBASE, Figure 2

#positioning

Material limitations are explicitly identified

The paper states that physiological ionic strength requires additional mitigation and that five clinical samples cannot establish clinical performance. These acknowledgements define relevant next steps even though the final claims remain too broad.

↳ Results, Figure 4C; Results, Clinical Sample Measurements with GFET and Simoa

Limitations

#methodological rigour

Clinical validation rests on five samples

The clinical comparison includes five moderate-to-severe TBI plasma samples and reports Pearson correlation rather than an agreement analysis. Mean recovery of 123% also indicates systematic cross-platform difference that correlation alone does not resolve.

↳ Results, Clinical Sample Measurements with GFET and Simoa, Figure 5B–C

#reporting

Deployment language exceeds demonstrated conditions

The Abstract and Conclusions present broad point-of-care, diagnostic, and prognostic potential, while samples are diluted 100-fold and the F(ab')2 advantage is absent at 0.1× and 1× PBS.

↳ Abstract; Results, Performance of GFET Devices, Figure 4C; Conclusions

#application pathway

Transferability remains largely untested

Testing is confined to one platform and narrow clinical cohort, with reported device-to-device mobility variation near 20% and only two weeks of refrigerated stability evidence.

↳ Results, Performance of GFET Devices, Figure 4D–F

Does this match your read? Add your assessment ↓

Nabu Commentary

The strongest evidence is the direct F(ab')2-versus-IgG comparison and the orthogonal surface characterization in Figures 2–4. The analytical advance is meaningful, but the clinical evidence in Figure 5 comprises only five TBI samples, uses correlation rather than agreement, and shows 123% mean recovery. The Abstract and Conclusions therefore overstate validation and point-of-care readiness, particularly because the fragment advantage is not retained at physiological ionic strength. The paper is best interpreted as an analytical proof of concept requiring stronger clinical and operational validation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.0±0.2

Contribution
3.6

The paper makes a concrete NfL-specific extension of fragment-functionalized GFET sensing and adds convergent PBASE-density measurements. The advance remains close to prior fragment-GFET work, while its clinical reach is limited by the five-sample comparison.

Introduction, final two paragraphs; Results, Molecular Density of PBASE; Figure 4B; Figure 5

Compared with whole antibody-based GFETs, this F(ab')2-modified GFET platform is shown to achieve a 114% increase in sensitivity.

Methodological Rigour
2.8

Orthogonal surface characterization, antibody-fragment quality checks, an IgG comparator, an ionic-strength series, cross-reactivity testing, and repeatability measurements support the analytical comparison. Methodological Rigour is limited by the narrow clinical spectrum, unclear independent-unit accounting for central calibrations, and reliance on correlation rather than agreement.

Figures 2–5; Statistical Analysis; Results, Clinical Sample Measurements with GFET and Simoa

this comparison was conducted using five clinical plasma samples

Reporting
3.0

The progression from surface chemistry through analytical performance to clinical comparison is easy to follow. However, the Abstract and Conclusions use validation, diagnostic, and deployment language that materially exceeds five diluted clinical samples and a correlation analysis.

Abstract; Results, Clinical Sample Measurements with GFET and Simoa; Conclusions

This biosensing platform is validated against Simoa technology

Positioning
2.8

The paper engages prior GFET, antibody-fragment, PBASE, and NfL assay literature and identifies physiological ionic strength and cohort size as limitations. Its final diagnostic and prognostic positioning nevertheless exceeds those acknowledged limits.

Introduction; Table 1; Results, Figures 4C and 5; Conclusions

validation in a larger cohort would be required

Reliability

No concerns4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyClean

No reporting or research-conduct concern supported by the supplied text was raised.

Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared

Reference IntegrityClean

59 references in manuscript 59 of 59 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Generic health relevance
Type of advanceMethodological
Route to useNamed
AdvanceExtends
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The platform is validated against Simoa on only five clinical plasma samples, a small pilot-level demonstration rather than an independent larger cohort.

From the paper
“These results demonstrate the potential of GFETs for point-of-care diagnosis and the monitoring of neurological diseases in frontline clinical settings”

The paper names frontline clinical settings and clinicians as the actors who would use the GFET platform for point-of-care diagnosis and monitoring of neurological diseases.

Pathway

Clinical teams in frontline and primary care settings would adopt the GFET platform for rapid point-of-care NfL measurement to diagnose and monitor neurological diseases.

Barrier

Validation in a larger clinical cohort is required, and operation at physiological ionic strength needs additional strategies to mitigate Debye screening for practical deployment.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Three-Dimensional (3D) in vitro cell culture protocols to enhance glioblastoma research

    Wanigasekara, Carroll, Cullen, et al. · 2023 · Clinical medicine

    Primary claim

    The expected results from these protocols confirmed the ability of all these methods to create uniform tumourspheres.

    Tentative
    Evidence Score
    2.9±0.2
    Reliability
    Concerns
  2. Robust clay binder for earth-based concrete

    Daria Ardant, Coralie Brumaud, Arnaud Perrot, et al. · 2023 · Civil engineering

    Primary claim

    We show that the solid volume fraction of clay paste is the key parameter allowing predicting the fresh state properties of the clay binder, whatever the constitutive clay type

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    Caveats
  3. Influence of additives on poured earth strength development

    Daria Ardant, Coralie Brumaud, Guillaume Habert · 2020 · Civil engineering

    Primary claim

    The results show that the dispersant has a strong impact on the compression strength of clay-based materials due to the optimized organization of the clay particles during the deflocculation step, leading to an increase in the capillary force intensity.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →